New trial
Phase II Adjuvant Trial: Evaluating Chemotherapy Omission in ER+/HER2– Breast Cancer
- Trial ID
- NCT06953882 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Published in
- New in Oncology - May 14, 2025
Yale University is investigating whether ribociclib combined with optimized endocrine therapy, minus adjuvant chemotherapy, improves treatment adherence and outcomes in moderate to high-anatomical risk, low-genomic risk, ER-positive, HER2-negative breast cancer. This trial aims to potentially reduce treatment-related toxicity and healthcare costs while maintaining clinical efficacy.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer